| Literature DB >> 27854508 |
Elizabeth P Harausz1, Anthony J Garcia-Prats2, James A Seddon3, H Simon Schaaf2, Anneke C Hesseling2, Jay Achar4, Jonathan Bernheimer5, Andrea T Cruz6, Lia D'Ambrosio7,8, Anne Detjen9, Stephen M Graham10, Jennifer Hughes5, Sylvie Jonckheere11, Ben J Marais12, Giovanni Battista Migliori7, Lindsay McKenna13, Alena Skrahina14, Marina Tadolini15, Peyton Wilson16, Jennifer Furin17.
Abstract
It is estimated that 33,000 children develop multidrug-resistant tuberculosis (MDR-TB) each year. In spite of these numbers, children and adolescents have limited access to the new and repurposed MDR-TB drugs. There is also little clinical guidance for the use of these drugs and for the shorter MDR-TB regimen in the pediatric population. This is despite the fact that these drugs and regimens are associated with improved interim outcomes and acceptable safety profiles in adults. This review fills a gap in the pediatric MDR-TB literature by providing practice-based recommendations for the use of the new (delamanid and bedaquiline) and repurposed (linezolid and clofazimine) MDR-TB drugs and the new shorter MDR-TB regimen in children and adolescents.Entities:
Keywords: Mycobacterium tuberculosis; adolescent; child; multidrug-resistant tuberculosis; pediatric
Mesh：
Substances：
Year: 2017 PMID： 27854508 DOI： 10.1164/rccm.201606-1227CI
Source DB: PubMed Journal: Am J Respir Crit Care Med ISSN： 1073-449X Impact factor: 21.405